AR093813A1 - Composiciones en suspension de finafloxacina - Google Patents

Composiciones en suspension de finafloxacina

Info

Publication number
AR093813A1
AR093813A1 ARP130104513A ARP130104513A AR093813A1 AR 093813 A1 AR093813 A1 AR 093813A1 AR P130104513 A ARP130104513 A AR P130104513A AR P130104513 A ARP130104513 A AR P130104513A AR 093813 A1 AR093813 A1 AR 093813A1
Authority
AR
Argentina
Prior art keywords
finafloxacine
suspension compositions
suspension
compositions
finafloxacin
Prior art date
Application number
ARP130104513A
Other languages
English (en)
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of AR093813A1 publication Critical patent/AR093813A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una composición en suspensión tópica que comprende finafloxacina, un solubilizante, y un agente de suspensión.
ARP130104513A 2012-12-06 2013-12-05 Composiciones en suspension de finafloxacina AR093813A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261734268P 2012-12-06 2012-12-06

Publications (1)

Publication Number Publication Date
AR093813A1 true AR093813A1 (es) 2015-06-24

Family

ID=50881613

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104513A AR093813A1 (es) 2012-12-06 2013-12-05 Composiciones en suspension de finafloxacina

Country Status (17)

Country Link
US (2) US9504691B2 (es)
EP (1) EP2928475B1 (es)
JP (1) JP5980440B2 (es)
KR (1) KR102175743B1 (es)
CN (2) CN104869999A (es)
AR (1) AR093813A1 (es)
AU (1) AU2013356488B2 (es)
BR (1) BR112015010927B1 (es)
CA (1) CA2888641C (es)
CL (1) CL2015001500A1 (es)
ES (1) ES2784653T3 (es)
MX (1) MX2015007182A (es)
PH (1) PH12015501230A1 (es)
RU (1) RU2693476C2 (es)
UA (1) UA115454C2 (es)
WO (1) WO2014088838A1 (es)
ZA (1) ZA201503102B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102014115951A1 (de) * 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
DE102015100068A1 (de) * 2015-01-06 2016-07-07 Merlion Pharmaceuticals Pte Ltd. Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832535B2 (ja) * 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
US5750564A (en) * 1995-09-12 1998-05-12 Hellberg; Mark Anti-oxidant esters of non-steroidal anti-inflammatory agents
DE19652239A1 (de) * 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
AR020661A1 (es) 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6685958B2 (en) * 2001-04-25 2004-02-03 Insite Vision Incorporated Quinolone carboxylic acid compositions and related methods of treatment
CZ303572B6 (cs) 2000-06-28 2012-12-12 Smithkline Beecham P. L. C. Jemne rozmelnený prostredek a zpusob jeho prípravy
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
US20040072809A1 (en) * 2002-07-30 2004-04-15 Omeros Corporation Ophthalmologic irrigation solutions and method
CA2516429A1 (en) * 2003-02-21 2004-10-14 Sun Pharmaceutical Industries Limited Stable ophthalmic formulation containing an antibiotic and a corticosteroid
WO2005123844A1 (de) * 2004-06-16 2005-12-29 Colour Ltd. Verfahren zur herstellung von beta-kupferphthalocyanin-blaupigmenten und deren verwendung
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AU2009214461A1 (en) * 2008-02-15 2009-08-20 Alcon Research, Ltd. Fluoroquinolone derivatives for ophthalmic applications
WO2010011942A1 (en) 2008-07-25 2010-01-28 Cox Raleigh L A switch and switch actuator
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
JP2010265261A (ja) * 2009-04-17 2010-11-25 Santen Pharmaceut Co Ltd レボカバスチン懸濁型点眼剤
AU2010266120B2 (en) * 2009-07-02 2014-02-06 Curofin Pharma Gmbh Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections
FR2950353B1 (fr) 2009-09-18 2012-01-13 Commissariat Energie Atomique Procede pour ameliorer les proprietes de resistance au frottement.

Also Published As

Publication number Publication date
PH12015501230A1 (en) 2015-08-17
WO2014088838A1 (en) 2014-06-12
US20160279137A1 (en) 2016-09-29
EP2928475A1 (en) 2015-10-14
MX2015007182A (es) 2015-10-12
UA115454C2 (uk) 2017-11-10
BR112015010927A2 (pt) 2017-07-11
KR20150090045A (ko) 2015-08-05
CN109908081A (zh) 2019-06-21
AU2013356488B2 (en) 2018-04-26
CN104869999A (zh) 2015-08-26
BR112015010927B1 (pt) 2022-05-10
CA2888641A1 (en) 2014-06-12
CA2888641C (en) 2021-02-23
JP5980440B2 (ja) 2016-08-31
ZA201503102B (en) 2016-11-30
US9504691B2 (en) 2016-11-29
US20140162990A1 (en) 2014-06-12
EP2928475B1 (en) 2020-03-04
RU2015126799A (ru) 2017-01-13
EP2928475A4 (en) 2016-05-11
KR102175743B1 (ko) 2020-11-06
AU2013356488A1 (en) 2015-04-23
ES2784653T3 (es) 2020-09-29
CL2015001500A1 (es) 2015-08-28
RU2693476C2 (ru) 2019-07-03
JP2016500079A (ja) 2016-01-07

Similar Documents

Publication Publication Date Title
CL2016001547A1 (es) Composiciones para el cuidado oral
MX2019010441A (es) Composiciones y metodos.
UY34332A (es) Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?.
UA117008C2 (uk) IN VITRO ТРАНСКРИБОВАНА мРНК ТА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ, ДЛЯ ЗАСТОСУВАННЯ В ЛІКУВАННІ МУКОВІСЦИДОЗУ В ССАВЦЯ
RS53818B1 (en) PIROLOBENZODIAZEPINI I NJIHOVI conjugated
CL2014001642A1 (es) Composicion detergente que conteniene n, n - diacetato glutamico y agente decolorante.
UY4236Q (es) Configuración aplicada en zapato
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
CO7160079A2 (es) Composiciones líquidas de racecadotrillo
CO7250444A2 (es) Uso de seaprose para eliminar biopelículas bacterianas
PH12015502014A1 (en) Racecadotril lipid compositions
PH12014502858A1 (en) Racecadotril lipid compositions
IN2014DN11078A (es)
BR112015027824A2 (pt) composições de vitamina e em pó
PH12015502061A1 (en) Racecadotril liquid compositions
RS53457B (en) COMPOSITION AND ITS APPLICATION IN THE TREATMENT OF ANAL RAGAD
AR093813A1 (es) Composiciones en suspension de finafloxacina
CL2015000847A1 (es) Formulaciones de aceite con aglutinantes
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
UY4233Q (es) Configuración aplicada en zapato
UY34826A (es) Composición fungicida sinérgica.
EP2978434A4 (en) COMPOSITIONS, FORMULATIONS AND METHODS FOR BIO-BALANCING THE PH OF ISOTONIC SALT SOLUTION AND STERILE HYPERTONIC SOLUTES
MX2015000984A (es) Composiciones antitranspirantes y metodos.
UY34865A (es) Una composición acuosa que comprende dicamba y un agente de control de la deriva
AR087666A1 (es) Composicion acondicionadora del cabello

Legal Events

Date Code Title Description
FB Suspension of granting procedure